Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 14;17:5265–5286. doi: 10.2147/IJN.S369761

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Wei et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

In vivo activity of PTX-SLN@CUD. (A) Variety of tumor volume in vivo anticancer trials. (B) Changes in mouse body weight (n=6 per group). (C) After 20 days of drug administration, the mice in each group were sacrificed, and tumor tissues were collected and imaged. (D) Ki-67 immunohistochemical staining of tumors excised from animals in the control, PTX, and CU-PTX-LN groups, respectively. (E) Tumor inhibitory rates (%) of MCF-7-bearing nude mice treated with free PTX and PTX-SLN@CUD on day 20, **p < 0.01 compared with PTX. (F) Tumor weights (mg) of MCF-7-bearing nude mice treated with PTX and PTX-SLN@CUD on day 20, after which the mice were humanely sacrificed, **p < 0.01, ****p < 0.0001, administration group vs control.